In August, we received €2.5 million in funding from the Health Research Board to continue to support the development of national clinical guidelines.
This four-year award will fund the Centre in Ireland for Clinical guideline support and Evidence Reviews (CICER), a partnership comprising HIQA, Trinity College Dublin and clinical and methodological experts, until 2028.
Speaking about the award, Dr Máirín Ryan, our Deputy CEO and Director of Health Technology Assessment, and CICER principal investigator, explained that CICER, which was formed in 2017, has provided support to over a dozen National Clinical Guidelines.
“This new grant supports us to continue our work, and I look forward to working with partners on synthesising up-to-date international evidence to inform crucial decisions for patients in Ireland,” Dr Ryan said.
The funding is intended to support CICER in its efforts to review the clinical and cost-effectiveness of interventions and to assess the budgetary implications of implementing guidelines.
It will build on research funding from a previous competitive process spanning the period from 2017 to 2024, during which CICER supported the development of National Clinical Guidelines to improve patient safety.
During this new phase of the grant, CICER will aim to strengthen public and patient involvement throughout the guideline development process, and to foster additional national and international collaborations.
(Pictured at the beginning of this article: Dr Máirín Ryan, HIQA’s Deputy CEO, with CICER team members.)